WASH Trial: Intraoperative Lavage as a Treatment for Pancreatic Cancer

Running, not enrolling · Not applicable

Conditions studied: Acinar Cell Carcinoma, Ampulla of Vater Adenocarcinoma, Cholangiocarcinoma, Duodenal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary Mucinous Neoplasm, Periampullary Adenocarcinoma

In brief

The goal of this clinical trial is to learn if a special washing treatment used during surgery can help people with pancreatic cancer live longer. The study includes adults who are having surgery for suspected pancreatic cancer or related cancers in nearby organs (called periampullary cancers). The main questions it aims to answer are: * Does the washing treatment improve overall survival (how long patients live)? * Does it improve how long patients remain cancer-free and reduce cancer recurrence or complications? The investigators will compare two types of washing treatments and standard care to see if either method improves outcomes. Participants will: Be assigned by chance (randomized) before surgery to one of three groups: * Washing with warm saltwater (saline) * Washing with sterile water * No extensive washing (standard care) Undergo their planned cancer surgery, during which the washing treatment (if assigned) will be performed right after the tumor is removed Be followed over time to monitor survival, cancer recurrence, and any side effects The investigators estimate the washing treatment could increase average survival from about 18 months to 27 months. To ensure enough patients with confirmed pancreatic cancer are included, about 845 participants will be enrolled over time.

Key facts

Study ID

NCT02757859

Run by

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

People needed

845

Starts

2016-04-27

Expected to finish

2031-05-01

Last updated by the study team

2026-05-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject has a surgical indication for pancreatectomy (pancreaticoduodenctomy, distal pancreatectomy, total pancreatectomy) as determined by the treating physician/surgeon
• A diagnosis of pancreatic or other periampullary cancer is suspected preoperatively
• In the opinion of the surgeon, the subject has no medical contraindications to pancreatectomy
• Age ≥18 years of age.
• The subject is willing to consent to randomization of EAL-S vs. EAL-W vs. no extensive lavage (SOC)

You may not qualify if…

• The subject does not have a surgical indication for pancreatectomy
• In the opinion of the surgeon, the subject has medical contraindications to pancreatectomy
• Age <18 years of age
• The subject is not willing to consent to EAL-S vs. EAL-W vs. no extensive lavage (SOC)
• Known benign or indolent disease (including benign pancreatic cystic tumors or pancreatic endocrine tumors) without possible risk of malignancy
• Other malignancy within five years, unless the probability of recurrence of the prior malignancy is <5% as determined by the Principal Investigator based on available information. Patient's curatively treated for squamous and basal cell carcinoma of the skin or patients with a history of malignant tumor in the past that have been disease free for at least five years are also eligible for this study.
• Evidence of metastatic disease preoperatively

Where it is running

• Sidney Kimmel Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.